2021
Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brain
2015
Animal models in regenerative medicine
Bubak A, Elsworth J, Sladek J. Animal models in regenerative medicine. 2015, 301-316. DOI: 10.1002/9781118846193.ch16.Peer-Reviewed Original ResearchAnimal modelsCurrent clinical therapeuticsClinical trialsStem cellsRegenerative medicineFuture clinical trialsAppropriate animal modelsHuman therapeuticsStem cell trialsCell trialsHuman studiesClinical settingClinical therapeuticsTranslational researchUnsuccessful trialsTrialsDiseaseSpecific diseasesChallenging goalOptimal techniqueTherapeuticsCellsLoss of confidence
1997
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor J, Elsworth J, Roth R, Sladek J, Redmond D. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81: 745-755. PMID: 9316026, DOI: 10.1016/s0306-4522(97)00214-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseSevere parkinsonismAdult male African green monkeysMale African green monkeysTetrahydropyridine-induced parkinsonismMPTP-induced parkinsonismIdiopathic Parkinson's diseaseNovel therapeutic treatmentsLong-term deficitsAfrican green monkeysGroups of animalsNon-human primatesMPTP treatmentParkinsonian monkeysMPTP administrationVervet monkeysFunctional deficitsInitial severityStable parkinsonismBehavioral deficitsAnimal modelsParkinsonismParkinsonian subjectsMPTPTherapeutic treatment